SHORT COMMUNICATION OPEN ACCESS

Genetic Etiology Influences the Low-Frequency Components of Globus Pallidus Internus Electrophysiology in Dystonia

Ahmet Kaymak^{1,2} \bigcirc | Luigi M. Romito³ | Fabiana Colucci^{3,4} | Nico Golfrè Andreasi³ | Roberta Telese³ | Sara Rinaldo³ | Vincenzo Levi⁵ | Giovanna Zorzi⁶ | Zvi Israel^{7,8} | David Arkadir^{8,9} | Hagai Bergman^{7,10,11} | Miryam Carecchio¹² \bigcirc | Holger Prokisch^{13,14} | Michael Zech^{13,14,15} | Barbara Garavaglia¹⁶ | Alberto Mazzoni^{1,2} | Roberto Eleopra³

¹The Biorobotics Institute, Scuola Superiore Sant'Anna, Pisa, Italy | ²Department of Excellence for Robotics and AI, Scuola Superiore Sant'Anna, Pisa, Italy | ³Movement Disorders Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | ⁴Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy | ⁵Neurosurgery Department, Functional Neurosurgery Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | ⁶Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy | ⁷Department of Neurosurgery, Hadassah Medical Center, Jerusalem, Israel | ⁸Faculty of Medicine, The Hebrew University, Jerusalem, Israel | ⁹Department of Neurology, Hadassah Medical Center, Jerusalem, Israel | ¹⁰Department of Medical Neuroscience, Institute of Medical Research Israel-Canada (IMRIC), the Hebrew University-Hadassah Medical School, Jerusalem, Israel | ¹¹The Edmond and Lily Safra Center for Brain Sciences, The Hebrew University, Jerusalem, Israel | ¹²Department of Neuroscience, University of Padova, Padova, Italy | ¹³Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany | ¹⁴Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany | ¹⁵Institute for Advanced Study, Technical University of Munich, Garching, Germany | ¹⁶Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Correspondence: Luigi M. Romito (luigi.romito@istituto-besta.it) | Alberto Mazzoni (alberto.mazzoni@santannapisa.it)

Received: 8 November 2024 | Revised: 10 February 2025 | Accepted: 14 February 2025

Funding: This research is supported by #Nextgenerationeu (NGEU) and funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project THE (IECS00000017)—Tuscany Health Ecosystem (DN. 1553 11.10.2022). A.K. was supported by the Italian Ministry of Research, under the complementary actions to the NRRP "Fit4MedRob—Fit for Medical Robotics" Grant (# PNC0000007). L.R. received research support from the Italian Ministry of Health (IMH) grant GR-2009-1594645 and from the European Academy of Neurology—EAN (formerly European Federation of Neurological Societies) Fellowship Award to young Neurologists 2007—EFNS Fellowship 2007. B.G. and G.Z. received support and grants from The Italian Ministry of Health (IMH) and the Pierfranco e Luisa Mariani Foundation. M.Z. receives research support from the German Research Foundation (DFG 458949627; ZE 1213/2–1) and acknowledges grant support from the European Joint Programme on Rare Diseases (EJP RD Joint Transnational Call 2022), the German Federal Ministry of Education and Research (BMBF, Bonn, Germany), the PreDYT project (PREdictive biomarkers in DYsTonia, 01GM2302), the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as well as the Technical University of Munich Institute for Advanced Study. D.A. is supported by a research grant from the Dystonia Medical Research Foundation (DMRF).

Keywords: alpha oscillations | deep brain stimulation | dystonia | electrophysiology | genetics

ABSTRACT

Background: Elevated low-frequency activity (4–12 Hz) within the globus pallidus internus (GPi) has been consistently associated with dystonia. However, the impacts of the genetic etiology of dystonia on low-frequency GPi activity remain unclear; yet it holds importance for adaptive deep brain stimulation (DBS) treatment.

© 2025 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Ahmet Kaymak and Luigi M. Romito contributed equally to this work.

The last two authors share senior authorship.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Results: DYT-*SGCE* patients exhibited significantly lower alpha band activity (2.97%) compared to iDYT (4.44%, p = 0.006) and DYT-*THAP1* (4.51%, p = 0.011). Additionally, theta band power was also significantly reduced in DYT-*SGCE* (4.42%) compared to iDYT and DYT-*THAP1* (7.91% and 7.00%, p < 0.05). Instead, the genetic etiology of dystonia did not affect the spatial characteristics of GPi electrophysiology along MER trajectories.

Conclusion: Considering the genetic etiology of dystonia in closed-loop DBS treatments and utilizing theta and alpha activity for GPi stimulation may optimize clinical outcomes. MER-based DBS lead placement can proceed independently of the underlying genetic cause.

1 | Introduction

Dystonia is a movement disorder causing abnormal, often repetitive movements or postures due to muscle contractions, with genetic forms resulting from pathogenic mutations in causative genes leading to diverse clinical presentations [1, 2]. Deep brain stimulation (DBS) targeting the globus pallidus internus (GPi) is an effective therapy for the drug-resistant form of dystonia [3]. Intraoperative microelectrode recordings (MERs) are routinely used to confirm the DBS lead placements, also reveal the pathophysiology of movement disorders [4, 5].

Elevated low-frequency (4–12 Hz) activity in local field potentials (LFPs) of the GPi [6, 7] and subthalamic nucleus (STN) [8, 9] has been consistently associated with dystonia. This activity could potentially serve as a biomarker for closed-loop DBS in dystonia [9, 10]. Therefore, examining the impact of genetic etiology on low-frequency GPi electrophysiology could enable personalized adaptive DBS (aDBS) treatments.

Herein, we compared the properties of low-frequency GPi activity extracted from MERs collected during GPi-DBS surgery from patients with various genetic and idiopathic forms of dystonia. A significant reduction in low-frequency activity (4–12 Hz) was observed in patients with DYT-*SGCE* compared to DYT-*THAP1* and idiopathic dystonia, highlighting the potential for personalized aDBS based on genetic factors in dystonia patients. Finally, our findings indicate that genetic etiology has no significant impact on the spatial characteristics of GPi electrophysiology. Therefore, MER-based DBS lead placement can be performed independently of the genetic etiology of dystonia.

2 | Materials and Methods

The study was conducted with genetic and idiopathic dystonia patients who underwent bilateral GPi-DBS surgery under propofol and remifentanil anesthesia (Table S1) at Fondazione IRCCS Istituto Neurologico Carlo Besta. Before 2000, only *TOR1A* was tested in patients. Between 2000 and 2015, individuals who were negative for *TOR1A* were retested via Sanger sequencing as new genes were identified. Since 2015, an NGS-customized dystonia gene panel has been employed [11], (Table S1).

The surgeries were conducted bilaterally and under stereotactic conditions with the Leksell (Elekta Inc.) or Maranello (Eidos22)

frames. A thorough description of our standard surgical procedure is available elsewhere [12]. Identification of the nuclei borders, the sensorimotor GPi, and MER depths was performed by using the Distal Atlas [13] in Montreal Neurological Institute space (p > 0.5 threshold) with Lead DBS v2.3 [14] and an expert electrophysiologist. At the preoperative and postoperative follow-up evaluations, the Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS) was employed to assess the motor severity. The demographic and clinical profiles of the patients are presented in Table 1.

We adopted the methodology used to compare STN electrophysiology in monogenetic and idiopathic forms of Parkinson's disease (PD) [15]. Briefly, we divided MERs into 50 ms segments, computed the root mean square (RMS), and labeled segments stable if their RMS values were within three standard deviations of the median RMS. The longest stable section of each recording was selected for further analysis [16]. To estimate the power spectral density (PSD), we rectified the stable raw signal and subtracted the mean to reveal the lowfrequency envelope. The PSD was estimated with a resolution of 1/3 Hz and normalized to the total power within the analysis range (2-200 Hz) to mitigate the influence of varying RMS values across patients [16]. The length of the detected GPi region was normalized to 1, where 0 represents the GPi entry [15]. Trajectories were included in analyses if they had a minimum GPi length of 2mm and recordings from at least four distinct depths (Figure S1). Theta (4-8 Hz), alpha (8-12 Hz), beta (12-30 Hz), and gamma (30-100), band activity was extracted using a four-pole Butterworth band-pass filter. The fraction of power and the ratio between these bands were measured as electrophysiological features.

Kruskal–Wallis and post hoc Dunn's test with Holm–Bonferroni correction were used for group comparison. Spearman's correlation with permutation testing was used to assess the significance of linear relationships between variables, with Benjamini/Hochberg (FDR) correction applied to the *p* values for measured correlations. All tests were two-tailed, and statistical significance was defined as $p \leq 0.05$. We employed a linear mixed model (LMM) with the Wald test to investigate the interaction between normalized depths and spectral properties within the GPi by considering genetic factors as random effects. This approach allowed us to assess the influence of GPi depth on spectral properties while accounting for random variation from genetic factors and individual differences.

i is and						Main			Pr	eoperative l	FMDRS-	M			Post	operative 1	Y-FU BFI	MDRS-M	
1 0.04.1 F 37 42 Coroial Plane 36 3 6 1 22 3 6 6 6 1 22 3 6 6 6 1 3 3 4 1 3 3 4 1 3 3 4 1 3 3 4 1 3 3 4 1 3 3 4 3 3 4 1 3 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 4 4 1 3 3 4 3 3 4 3 3 4 3 3 3 3 3 3 3 4 3 3 3 3 4 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	Id	Gene	Sex	Age onset	Age at surgery	body part	Pattern	Total	Arms	Cranial	Neck	Legs	Trunk	Total	Arms	Cranial	Neck	Legs	Trunk
10101112131413141314 <td>P1</td> <td>GNAL</td> <td>ц</td> <td>37</td> <td>42</td> <td>Cervical</td> <td>Phasic</td> <td>26</td> <td>~</td> <td>0</td> <td>9</td> <td>0</td> <td>12</td> <td>22</td> <td>~</td> <td>0</td> <td>9</td> <td>0</td> <td>×</td>	P1	GNAL	ц	37	42	Cervical	Phasic	26	~	0	9	0	12	22	~	0	9	0	×
10 MMTB 10 25 Total 10 27 10 27 10 27 27 27 </td <td>P2</td> <td>GNAL</td> <td>ц</td> <td>42</td> <td>63</td> <td>Cervical</td> <td>Phasic</td> <td>24</td> <td>10</td> <td>9</td> <td>9</td> <td>0</td> <td>7</td> <td>14</td> <td>Ŋ</td> <td>с</td> <td>4</td> <td>0</td> <td>2</td>	P2	GNAL	ц	42	63	Cervical	Phasic	24	10	9	9	0	7	14	Ŋ	с	4	0	2
W M N	P3	KMT2B	Μ	28	45	Trunk	Tonic	27	4	с	8	0	12	10	1	0	ŝ	0	9
Norm Norm <th< td=""><td>P4</td><td>KMT2B</td><td>Μ</td><td>8</td><td>16</td><td>Upper</td><td>Phasic</td><td>28</td><td>13</td><td>0</td><td>9</td><td>6</td><td>0</td><td>14</td><td>S</td><td>0</td><td>ŝ</td><td>9</td><td>0</td></th<>	P4	KMT2B	Μ	8	16	Upper	Phasic	28	13	0	9	6	0	14	S	0	ŝ	9	0
16 SGCF 10 17 Upper Faile 16 7 1 <th1< th=""> <th1< th=""> 1 <</th1<></th1<>	P5	SGCE	Μ	2	48	Upper	Phasic	11.5	9	1.5	1	2	1	10.5	S	1.5	1	2	1
	P6	SGCE	Μ	3	17	Upper	Phasic	16	7	0	4	4	1	2.5	1	0	0.5	1	0
With F 7 32 Turk Total 23 4 4 1 1 2 Turk 1 2 Turk 7 2 Turk 7 2 Turk 7 2 Turk 10 1 2 Turk 10 1 2 10 1 2 10 1 2 10 10 1 2 10	Ρ7	THAP1	Ц	40	14	Cervical	Tonic	17	4	ŝ	8	1	1	20	2	8	8	1	1
11 11 1 6 7 1 1 1 4 1 4 5 1 1 1 1 4 5 1 1 1 4 5 1 1 1 4 5 1	P8	THAPI	ц	7	32	Trunk	Tonic	32.5	4	4	0.5	12	12	5	0	0	0	ŝ	2
	$\mathbf{P9}$	THAPI	Μ	9	46	Cervical	Tonic	45	4	9	8	15	12	20	2	1.5	4.5	3	6
	P10	THAPI	Μ	14	43	Cervical	Tonic	60.5	13	12.5	8	15	12	31	11	4.5	4.5	2	6
	P11	TOR1A	Μ	14	49	Upper	Phasic	30.5	20	0.5	4	5	1	24.5	16	0.5	4	3	1
	P12	TOR1A	Μ	13	6	Lower	Tonic	29.5	0	0	0.5	20	6	4	0	0	0	2	2
	P13	TOR1A	Μ	10	33	Upper	Tonic	25	13	1	0	6	2	18	10	1	0	5	2
15 $70R14$ M1244CervialTonic36160668197062416 $70R14$ M109LowerTonic23570051041510622417 $70R14$ F1123UpperTonic2357001310415110.5622119 $70R14$ F1123UpperTonic34242.50.50.5101710161022110 $70R14$ M843TrunkTonic2371122017131710212210 $VFS16$ M151249TrunkTonic237112201713132110 $VFS16$ M1314201310113131012112131012121212121212121212121212121212121212131212131212121312121212121212121212121212121	P14	TOR1A	ц	7	47	Lower	Tonic	43	14	0	0	25	4	4	2	0	0	2	0
16 $70RIA$ M 10 9 LowerTonic 235 7 0 05 13 10 4 15 05 2 2 2 17 $70RIA$ F 11 23 UpperTonic 39 24 25 05 10 175 2 1 0.5 6 8 191 $70RIA$ F 11 23 UpperTonic 39 24 25 0 1 175 2 1 0.5 6 8 192 $70RIA$ M 8 43 Tonic 34 0 0 0 10 13 175 10 0.5 0 102 $VPSI6$ M 15 43 $70mid$ 23 12 11 23 12 10 0 0 12 13 12 12 0 0 0 12 12 12 10 12	P15	TOR1A	Μ	12	44	Cervical	Tonic	36	16	0	9	9	∞	19	7	0	9	2	4
	P16	TOR1A	Μ	10	6	Lower	Tonic	23.5	7	0	0.5	13	б	10	4	1.5	0.5	2	2
18 $TORIA$ M843TrunkTonic34001816300021P19 $VPSI6$ F1249CranialTonic2371122113.5740.50221P20 $VPSI6$ M1545CervicalPhasic231200113.5740.5022P21 $VPSI6$ M1424TrunkTonic52.5200.56141225.5120.5632212P21 $VPSI6$ M1424TrunkTonic52.5200.56141225.512652217221P22DIOPATHICF4233CervicalPhasic311051225176151712221P23DIOPATHICF4357CranialTonic4522221712221712212 <td>P17</td> <td>TORIA</td> <td>ц</td> <td>11</td> <td>23</td> <td>Upper</td> <td>Tonic</td> <td>59</td> <td>24</td> <td>2.5</td> <td>0.5</td> <td>20</td> <td>12</td> <td>17.5</td> <td>2</td> <td>1</td> <td>0.5</td> <td>9</td> <td>8</td>	P17	TORIA	ц	11	23	Upper	Tonic	59	24	2.5	0.5	20	12	17.5	2	1	0.5	9	8
P19VPS16F1249CranialTonic2371122113.5740.502P20VPS16M1545CervicalPhasic32126655615.5354.5112P21VPS16M1424TrunkTonic52.5200.56141225.5120.565P22IDIOPATHICF4238CervicalPhasic311051225.51765522P23IDIOPATHICF4238CervicalPhasic311051225.51765622P24IDIOPATHICF4357CranialTonic452283012156262P24IDIOPATHICF6149CranialTonic4522830121534602P24IDIOPATHICF3530CervialPasic32.522830121310212P24IDIOPATHICF3530CervialPasic32.52283012131012121212121212 <t< td=""><td>P18</td><td>TORIA</td><td>Μ</td><td>~</td><td>43</td><td>Trunk</td><td>Tonic</td><td>34</td><td>0</td><td>0</td><td>0</td><td>18</td><td>16</td><td>3</td><td>0</td><td>0</td><td>0</td><td>2</td><td>1</td></t<>	P18	TORIA	Μ	~	43	Trunk	Tonic	34	0	0	0	18	16	3	0	0	0	2	1
P20 $VPS16$ M1545CervicalPhasic3212661155354.512 $P21$ $VPS16$ M1424TrunkTonic52.5200.56141225.5120.5652 $P22$ DIOPATHICF4238CervicalPhasic311051225.5120.5672 $P23$ DIOPATHICF4238CervicalPhasic31105122227176261 $P23$ DIOPATHICF6149CranialTonic4522830121534602 $P24$ DIOPATHICF6149CranialTonic4522830121534602 $P24$ DIOPATHICF6149CranialTonic4522830121534602 $P24$ DIOPATHICF6149CranialTonic452283012151710171012 $P24$ DIOPATHICF5330CervicalPhasic32.5228861219101210121012	P19	VPS16	н	12	49	Cranial	Tonic	23	7	11	2	2	1	13.5	7	4	0.5	0	2
P21 VPS16 M 14 24 Trunk Tonic 52.5 20 0.5 6 5 2 2 P22 IDIOPATHIC F 42 38 Cervical Phasic 31 10 5 12 25.5 12 6 5 2 1 P23 IDIOPATHIC F 42 38 Cervical Phasic 31 10 5 12 12 15 14 6 2 6 2 1 P23 IDIOPATHIC M 3 57 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 2 2 P24 IDIOPATHIC F 53 3 0 12 15 15 1 6 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 <	P20	VPS16	Μ	15	45	Cervical	Phasic	32	12	9	9	2	9	15.5	ю	5	4.5	П	2
P22 IDIOPATHIC F 42 38 Cervical Phasic 31 10 5 17 6 2 6 2 1 P23 IDIOPATHIC M 3 57 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 0 2 P24 IDIOPATHIC F 61 49 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 0 2 P24 IDIOPATHIC F 61 49 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 0 2 2 P25 IDIOPATHIC F 35 30 Cervical Pasic 32.5 2 8.5 8 6 8 5 1 0 3 0 1 P25 IDIOPATHIC F 35 0 12 15 1 0 1 1 1	P21	VPS16	Μ	14	24	Trunk	Tonic	52.5	20	0.5	9	14	12	25.5	12	0.5	9	5	2
P23 IDIOPATHIC M 3 57 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 0 2 P24 IDIOPATHIC F 61 49 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 0 2 P25 IDIOPATHIC F 35 30 Cervical Pasic 32.5 2 8.5 8 6 8 5 1 0 3 0 1 P26 IDIOPATHIC F 35 30 Cervical Pasic 32.5 2 8.5 8 6 8 5 1 0 3 0 1 P26 IDIOPATHIC M 39 60 Cervical Tonic 50 28 2 8 0 12 9 5 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 <td< td=""><td>P22</td><td>IDIOPATHIC</td><td>ц</td><td>42</td><td>38</td><td>Cervical</td><td>Phasic</td><td>31</td><td>10</td><td>5</td><td>12</td><td>2</td><td>2</td><td>17</td><td>9</td><td>2</td><td>9</td><td>2</td><td>1</td></td<>	P22	IDIOPATHIC	ц	42	38	Cervical	Phasic	31	10	5	12	2	2	17	9	2	9	2	1
P24 IDIOPATHIC F 61 49 Cranial Tonic 45 2 28 3 0 12 15 3 4 6 0 2 P25 IDIOPATHIC F 35 30 Cervical Phasic 32.5 2 8.5 8 6 8 5 1 0 3 0 1 P26 IDIOPATHIC F 35 30 Cervical Phasic 32.5 2 8.5 8 6 8 5 1 0 3 0 1 P26 IDIOPATHIC M 39 60 Cervical Tonic 50 28 2 8 0 12 9 5 0 4 0 0 1	P23	IDIOPATHIC	Μ	б	57	Cranial	Tonic	45	2	28	3	0	12	15	ю	4	9	0	2
P25 IDIOPATHIC F 35 30 Cervical Phasic 32.5 2 8.5 8 6 8 5 1 0 3 0 1 P26 IDIOPATHIC M 39 60 Cervical Tonic 50 28 2 8 0 12 9 5 0 4 0 0	P24	IDIOPATHIC	ц	61	49	Cranial	Tonic	45	7	28	3	0	12	15	б	4	9	0	2
P26 IDIOPATHIC M 39 60 Cervical Tonic 50 28 2 8 0 12 9 5 0 4 0 0	P25	IDIOPATHIC	ц	35	30	Cervical	Phasic	32.5	2	8.5	8	9	8	5	1	0	ю	0	1
	P26	IDIOPATHIC	Μ	39	60	Cervical	Tonic	50	28	2	8	0	12	6	5	0	4	0	0

-
468
133
1.2
202
5,3
θ
8
nlo
ade
dfi
ĝ
H
ps:
^{on}
Inc
Ē
3
3
ley.
8
nd d
2
2
Ξ
l/er
.e.,
800
8
ΎH
eh
F
Z
Zen
fμ
Ν
fue.
nch
ten .
Der
itse.
hes
Fo
rsc
h
8
entr
E H
5
iley
ò
Ē
e L
j.
Ę
8
6
0
-53
202
2025].
/2025]. See
[/2025]. See the
[/2025]. See the Te
i/2025]. See the Term
i/2025]. See the Terms ar
[2025]. See the Terms and C
[2025]. See the Terms and Conc
[2025]. See the Terms and Condition
[2025]. See the Terms and Conditions
[2025]. See the Terms and Conditions (http://www.ice.com/ ice.c
i/2025]. See the Terms and Conditions (https://
i/2025]. See the Terms and Conditions (https://onl
i/2025]. See the Terms and Conditions (https://online.
i/2025]. See the Terms and Conditions (https://onlinelibra
[2025]. See the Terms and Conditions (https://onlinelibrary.
[2025]. See the Terms and Conditions (https://onlinelibrary.wik
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.c
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com.
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/ter.
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-co.
i/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-condit.
(2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-condition.
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) o
i/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on W
(2025). See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wile
(2025). See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley O.
(2025). See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Onlin
(2025). See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online L
i/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Libr.
/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library .
/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rule
[2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of us
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; C
i/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA.
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA artic
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are go
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are gover
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the ap,
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applic
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable applicable and a set of the set o
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable C.
/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creat
/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Co.
2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Comm
/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons
/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons Lic

3 | Results

In total, 597 MERs were collected from 70 trajectories across 30 patients in the cohort (Table S2). All analyzed MER trajectories passed through the sensorimotor portion of the GPi. Therefore, we do not anticipate spatial confounders affecting the electrophysiology (Figure 1A).

Elevated relative power in the theta and alpha bands compared to the baseline (median power of the whole spectrum up to 100 Hz) was observed across dystonia syndromes (Figures S2 and S3). We detected statistically significant differences between patient groups in all spectral features except for the alpha/theta ratio ($p \le 0.05$, Kruskal–Wallis test with Holm–Bonferroni correction) (Table S4). The fraction of alpha band activity remained significantly lower for DYT-SGCE (2.97%) compared to iDYT (4.44%, p = 0.006, Dunn's test with Holm-Bonferroni correction) and DYT-THAP1 (4.51%, p = 0.011) patients (Figure 1B). Similarly, the fraction of power in the theta band was significantly lower in DYT-SGCE (4.42%) compared to the iDYT (7.91%, p = 0.002) and DYT-THAP1 (7.00%, p = 0.019) (Figure 1B,C). The fraction of gamma power for the DYT-VPS16 group (37.04%) was significantly higher than the remaining groups, apart from DYT-SGCE (Figure 1B).

We investigated whether the observed electrophysiological differences were linked to motor symptom severity rather than genetic etiology. This was accomplished by calculating Spearman's correlation between the median values of electrophysiological features for patients and their corresponding baseline BFMDRS scores, as well as the percentage change observed in these scores between the preoperative and postoperative evaluations (Figure 1D). We observed a moderate effect size (0.4–0.6) in the relationship between certain clinical and spectral feature pairs, but none reached statistical significance (p > 0.05, Spearman's correlation with FDR correction) (Figure 1D). Although no significant correlation was found, the power spectral characteristics of the GPi in iDYT cases appeared to be more associated with disease severity compared to genetic dystonia syndromes (Figure S4).

Additionally, we sought to elucidate the spatial characteristics of GPi electrophysiology along MER trajectories by measuring the linear relationship between the normalized depths (GPi entry=0, GPi exit=1) and spectral features. The beta/theta and beta/alpha ratios (r_s =0.30, p=0.049) demonstrated significant linear characteristics between the borders of the GPi in DYT-*VPS16* patients (Figure 1E). Finally, no evidence was found to support the role of genetic etiology in spatially modulating the electrophysiological properties of MER recordings within the GPi (LMM, Wald test with Holm–Bonferroni correction, p > 0.05) (Table S5).

4 | Discussion

Here, we presented the potential of dystonia genetic etiology to influence the low-frequency components of GPi electrophysiology. Reductions in theta and alpha band activities were observed in DYT-*SGCE* compared to DYT-*THAP1* and iDYT patients. These differences cannot be attributed to the severity of

					Main			Pr	eoperative E	FMDRS-	M			Poste	operative 13	Y-FU BFN	IDRS-M	
pI	Gene	Sex	Age onset	Age at surgery	body part	Pattern	Total	Arms	Cranial	Neck	Legs	Trunk	Total	Arms	Cranial	Neck	Legs	Trunk
P27	IDIOPATHIC	Μ	35	31	Cervical	Tonic	40.5	18	10.5	6	2	4	19	10	6.5	1.5	0	1
P28	IDIOPATHIC	Μ	19	42	Cervical	Phasic	35.5	4	8.5	8	33	12	19	0	7	9	33	8
P29	IDIOPATHIC	Ц	51	63	Cervical	Tonic	26	7	0	9	9	12	21	2	0	4	9	6
P30	IDIOPATHIC	М	3	45	Trunk	Tonic	43	10	14	9	4	6	33	8	11	4	4	9

TABLE 1 | (Continued)



FIGURE 1 | Electrophysiological characterization of power spectral properties of GPi for genetic and idiopathic dystonia syndromes. (A) Reconstruction of MER trajectories in MNI space, color-coded according to genetic etiology. (B) Statistical comparison of power spectral features was performed with Dunn's test with Holm–Bonferroni correction; significant results are indicated by color coding. (C) Box plots displaying the distributions of theta and alpha power fraction across dystonia groups. (D) Correlation matrix depicting linear relationship between spectral and clinical features, as determined by Spearman's correlation coefficient. The magnitude of each correlation score is indicated by the size and color of the marker. Regression plots highlight significant correlations between selected feature pairs, with scatter color-coded based on the genetic etiology. (E) Heatmap showing the correlation between normalized depth levels and electrophysiological features across patient groups. Regression plots depict the behavior of selected electrophysiological features along normalized depth levels, with the degree of correlation indicated by Spearman's correlation coefficient.

dystonia, as no significant correlation was found between these components and the severity of motor symptoms. We further demonstrated that the genetic etiology of dystonia is irrelevant to MER-based lead localization in GPi-DBS surgeries, as the spatial characteristics of spectral features remain consistent when genetic factors are treated as random effects in LMM.

Weill and colleagues proposed that genetic heterogeneity in PD is not associated with robust electrophysiological differences in STN [15]. In our case, we found significant differences between the low-frequency activity of DYT-*SGCE* from DYT-*THAP1* and iDYT in the GPi. It has been proposed that distinct oscillatory circuit disruptions may underlie dystonia and parkinsonism, even in the same anatomical structure [9]. In this context, the effects of genetic etiology on different movement disorders and brain regions can exhibit differences. Our results align with this study, as we did not observe any impact of genetic etiology on the spatial characteristics of GPi electrophysiology.

We previously analyzed the pallidal single-unit activity in a larger genetic dystonia cohort [17], including the patients analyzed here. We observed convergence among dystonia genes toward either strong bursts or tonic behavior, with *SGCE* and *THAP1* exhibiting opposite behaviors. This is consistent with the differing low-frequency activity of the GPi associated with these two genes at the population level in the present work [17].

It should be noted that our study has several limitations. The limited sample size may impact the findings, though the high number of single MER epochs could mitigate this to some extent. The limited number of trajectories per patient prevented a consistent evaluation of potential spatial confounding factors along the anteroposterior and mediolateral directions. Lastly, electrophysiological activity recorded from the GPi using microelectrodes reflects considerably smaller neuronal populations compared to LFPs recorded with DBS macroelectrodes. Therefore, the potential effects of genetic etiology should also be investigated in LFP recordings.

In conclusion, we suggest the genetic etiology may potentially impact low-frequency activity within the GPi, especially in patients with DYT-*SGCE*, where these bands seem to be underrepresented. An adaptive DBS paradigm for dystonia based on the spectral fluctuations of recorded activity should then take into account potential differences between genetic dystonia profiles. However, further studies with larger sample sizes and a broader range of dystonia genes are needed to evaluate the clinical relevance of our hypothesis.

Author Contributions

Ahmet Kaymak: conceptualization, methodology, software, data curation, investigation, validation, formal analysis, visualization, project administration, writing – original draft, writing – review and editing. Luigi M. Romito: conceptualization, methodology, data curation, validation, supervision, project administration, resources, writing – original draft, writing – review and editing. Fabiana Colucci: data curation, investigation, writing – review and editing. Nico Golfrè Andreasi: data curation, writing – review and editing. Roberta Telese: data curation. Sara Rinaldo: data curation. Vincenzo Levi: data curation, writing – review and editing. Giovanna Zorzi: data curation. Zvi Israel: supervision. David Arkadir: supervision, writing – review and editing. Hagai Bergman: supervision. Miryam Carecchio: supervision. Holger Prokisch: supervision. Michael Zech: supervision, writing – review and editing. Barbara Garavaglia: data curation, investigation, validation. Alberto Mazzoni: conceptualization, methodology, validation, supervision, funding acquisition, project administration, writing – original draft, writing – review and editing. Roberto Eleopra: supervision.

Acknowledgments

The authors express their gratitude to Francesco Carella, who performed most of the intraoperative microrecordings. Open access publishing facilitated by Scuola Superiore Sant'Anna, as part of the Wiley - CRUI-CARE agreement.

Ethics Statement

The study was approved by the Ethical Committee of Fondazione IRCCS Istituto Neurologico Carlo Besta.

Consent

Informed consent was obtained from patients and their legal representatives.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The processed spectral datasets (both spectral features and normalized PSD) from MER data supporting the findings of this study are openly available in Zenodo at https://doi.org/10.5281/zenodo.14800798 in a tabular and fully anonymized format.

The complete code for data processing, descriptive analyses, and plotting is available online on the GitHub repository: https://github.com/ ahmetofficial/Genetic-DYT-GPi-Spectral-Activity/.

References

1. A. Albanese, K. Bhatia, S. B. Bressman, et al., "Phenomenology and Classification of Dystonia: A Consensus Update," *Movement Disorders* 28, no. 7 (2013): 863–873, https://doi.org/10.1002/mds.25475.

2. L. M. Lange, P. Gonzalez-Latapi, R. Rajalingam, et al., "Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force—An Update," *Movement Disorders* 37, no. 5 (2022): 905–935, https://doi.org/ 10.1002/mds.28982.

3. S. Tisch and K. R. Kumar, "Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome," *Frontiers in Neurology* 11 (2021): 630391, https://doi.org/10.3389/fneur.2020.630391.

4. C. P. Mosher, A. N. Mamelak, M. Malekmohammadi, N. Pouratian, and U. Rutishauser, "Distinct Roles of Dorsal and Ventral Subthalamic Neurons in Action Selection and Cancellation," *Neuron* 109, no. 5 (2021): 869–881, https://doi.org/10.1016/j.neuron.2020.12.025.

5. A. Kaymak, M. Vissani, M. Lenge, et al., "Patterns of Neural Activity and Clinical Outcomes in a Juvenile Huntington's Disease Patient Undergoing Deep Brain Stimulation of the Subthalamic Nucleus," *Deep Brain Stimulation* 1 (2023): 15–19, https://doi.org/10.1016/j.jdbs.2023.03.001.

6. W. Neumann, A. Horn, S. Ewert, et al., "A Localized Pallidal Physiomarker in Cervical Dystonia," *Annals of Neurology* 82, no. 6 (2017): 912–924, https://doi.org/10.1002/ana.25095.

7. G. Zhu, X. Geng, Z. Tan, et al., "Characteristics of Globus Pallidus Internus Local Field Potentials in Hyperkinetic Disease," *Frontiers in Neurology* 9 (2018): 934, https://doi.org/10.3389/fneur.2018.00934. 8. X. Geng, J. Zhang, Y. Jiang, et al., "Comparison of Oscillatory Activity in Subthalamic Nucleus in Parkinson's Disease and Dystonia," *Neurobiology of Disease* 98 (2017): 100–107, https://doi.org/10.1016/j.nbd.2016. 12.006.

9. W. Neumann, J. Huebl, C. Brücke, et al., "Enhanced Low-Frequency Oscillatory Activity of the Subthalamic Nucleus in a Patient With Dystonia," *Movement Disorders* 27, no. 8 (2012): 1063–1066, https://doi.org/10.1002/mds.25078.

10. S. Tisch and P. Limousin, "Neurophysiological Insights in Dystonia and Its Response to Deep Brain Stimulation Treatment," *Experimental Brain Research* 238, no. 7–8 (2020): 1645–1657, https://doi.org/10.1007/s00221-020-05833-8.

11. C. Reale, C. Panteghini, M. Carecchio, and B. Garavaglia, "The Relevance of Gene Panels in Movement Disorders Diagnosis: A Lab Perspective," *European Journal of Paediatric Neurology* 22, no. 2 (2018): 285–291, https://doi.org/10.1016/j.ejpn.2018.01.013.

12. V. Levi, G. Zorzi, G. Messina, et al., "Deep Brain Stimulation Versus Pallidotomy for Status Dystonicus: A Single-Center Case Series," *Journal of Neurosurgery* 134, no. 1 (2021): 197–207, https://doi.org/10.3171/2019.10.JNS191691.

13. S. Ewert, P. Plettig, N. Li, et al., "Toward Defining Deep Brain Stimulation Targets in MNI Space: A Subcortical Atlas Based on Multimodal MRI, Histology and Structural Connectivity," *NeuroImage* 170 (2018): 271–282, https://doi.org/10.1016/j.neuroimage.2017.05.015.

14. A. Horn, N. Li, T. A. Dembek, et al., "Lead-DBS v2: Towards a Comprehensive Pipeline for Deep Brain Stimulation Imaging," *NeuroImage* 184 (2019): 293–316, https://doi.org/10.1016/j.neuroimage.2018.08.068.

15. C. Weill, A. Gallant, H. Baker Erdman, et al., "The Genetic Etiology of Parkinson's Disease Does Not Robustly Affect Subthalamic Physiology," *Movement Disorders* 38, no. 3 (2023): 484–489, https://doi.org/10. 1002/mds.29310.

16. A. Zaidel, A. Spivak, L. Shpigelman, H. Bergman, and Z. Israel, "Delimiting Subterritories of the Human Subthalamic Nucleus by Means of Microelectrode Recordings and a Hidden Markov Model," *Movement Disorders* 24, no. 12 (2009): 1785–1793, https://doi.org/10.1002/mds.22674.

17. A. Kaymak, F. Colucci, M. Ahmadipour, et al., "Spiking Patterns in the Globus Pallidus Highlight Convergent Neural Dynamics Across Diverse Genetic Dystonia Syndromes," *Annals of Neurology* 30 (2025): 27185, https://doi.org/10.1002/ana.27185.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.